Stock ELTX ELICIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

End-of-day quote Nasdaq
Other stock markets
 23:00:00 26/06/2024 BST 		5-day change 1st Jan Change
6.89 USD +6.99% Intraday chart for Elicio Therapeutics, Inc. +4.08% -17.39%
06-28 Elicio Therapeutics Stock Falls After $11.5 Million Underwritten Public Offering Priced MT
06-28 Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
GL
Elicio Therapeutics Announces Proposed Public Offering
GL
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
GL
Elicio Therapeutics Reports Inducement Grants
AQ
Elicio Therapeutics : AMPLIFY 7P, a first in human safety and efficacy trial of adjuvant mKRAS specific lymph node targeted Amphiphile ELI 002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)
PU
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
AQ
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
AQ
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
GL
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
GL
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
GL
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
GL
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
GL
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
GL
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
GL
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
GL
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELTX Stock
  4. News Elicio Therapeutics, Inc.
  5. Press Releases